Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
Summary
LOr\xe9al to acquire a 10% stake in Galderma recognizing its dermatology category leadership and long-term growth potential Zug, Switzerland, August 5, 2024 Galderma today announced that it has signed a memorandum of understanding with LOr\xe9al to work towards a new research and development (R&D) collaboration in the form of a scientific partnership focused on complementary research projects which could develop advanced, future-proof technologies with direct applications in the field of dermatology.Todays announcement enables Galderma and LOr\xe9al to pursue new avenues and accelerate innovation in the field of dermatology in order to deliver new combined levels of performance against the signs of skin aging. As we continue to deliver outstanding performance across our blockbuster platforms in attractive dermatology market segments, our commitment to progressing our current late-stage pipeline and advancing science and innovation remain a cornerstone of our approach. Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Since our foundation in 1981, we have dedicated our focus and passion to the human bodys largest organ the skin meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. With our broad portfolio of 37 international brands and ambitious sustainability commitments in our LOr\xe9al for the Future program, we offer each and every person around the world the best in terms of quality, efficacy, safety, sincerity and responsibility, while celebrating beauty in its infinite plurality.